(Q35677641)

English

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study

scientific article published on 8 December 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ocular hypertension

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert N Weinreb

1

object named as

Robert N Weinreb

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Tuyen Ong

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Baldo Scassellati Sforzolini

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Jason L Vittitow

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Kuldev Singh

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Paul L Kaufman

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

VOYAGER study group

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

8 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

British Journal of Ophthalmology

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

738-745

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Nitric oxide (NO): an emerging target for the treatment of glaucoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

The pathophysiology and treatment of glaucoma: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

Rho-kinase inhibitors offer a new approach in the treatment of glaucoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

Effect of nitric oxide on anterior segment physiology in monkeys

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

eNOS, a pressure-dependent regulator of intraocular pressure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

Effect of nitric oxide compounds on monkey ciliary muscle in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

Activation of the BK(Ca) channel increases outflow facility and decreases trabecular meshwork cell volume

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

Risk assessment in the management of patients with ocular hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

Alterations of ocular nitric oxide synthase in human glaucoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

27 July 2018

Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

25 September 2018

An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

25 September 2018

Advances in glaucoma treatment and management: outflow drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

25 September 2018

The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

25 September 2018

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

25 September 2018

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453588

25 September 2018

Primary open-angle glaucoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BJOPHTHALMOL-2014-305908

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35677641&oldid=1561849037"